Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1049-1053

  Kelaidi, C ^a   Park, S ^a   Brechignac, S ^a   Mannone, L ^a   Vey, N ^a   Dombret, H ^a   Aljassem, L ^a   Stamatoullas, A ^a   Ades L ^a   Giraudier, S ^a   de Botton, S ^a   Raynaud, S ^a   Lepelley, P ^a   Picard, F ^a   Leroux, G ^a   Daniel, M T ^a   Bouscary, D ^a   Dreyfus, F ^a   Fenaux, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

5q deletion; EPO; Myelodysplastic syndromes; Thalidomide

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THALIDOMIDE;

5Q- SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 41949092882     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.037     Document Type: Article

References (26)

1. Van den Berghe H., Vermaelen K., Mecucci C., Barbieri D., and Tricot G. The 5q-anomaly. Cancer Genet Cytogenet 17 (1985) 189-255
2. Van den Berghe H., and Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 94 (1997) 1-7
3. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House. Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
4. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarre M.C., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 July (2) (2004) 321-327
5. Mannone L., Gardin C., Quarre M.C., Bernard J.F., Vassilieff D., Ades L., et al., For the Groupe Francais des Myelodysplasies (GFM). High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133 (2006) 513-519
6. Park S., Kelaidi C., Grabar S., Beyne-Rauzy O., Cheze S., Bardet V., et al. Prognostic factors and response duration in 419 MDS treated with erythropoietin ± GCSF: the GFM experience. Blood (2007) online
7. Ades L., Mohamed H., Vassilief D., Berger E., Slama B., Vey N., et al. Is there a role for ATRA in combination to EPO in lower risk myelodysplastic syndromes? Preliminary results of a phase II study. Blood 108 Suppl. 1 (2005) 712a
8. Bouscary D., Legros L., Tulliez M., Dubois S., Mahe B., Beyne-Rauzy O., et al., For The Groupe Francais des Myelodysplasies (GFM). A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 131 (2005) 609-618
9. Tamburini J., Elie C., Vassilief D., Quarre M.C., Beyne-Rauzy O., Gardembas M., et al. Low doses of thalidomide in low risk MDS with transfusion-dependent anemia: the GFM THAL-SMD-200 trial. Blood 106 Suppl. 1 (2006) 756a
10. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. World Health Organization(WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic. Blood 96 (2000) 3671-3674
11. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 July (2) (2006) 419-425
12. Negrin R.S., Stein R., Vardiman J., Doherty K., Cornwell J., Krantz S., et al. Treatment of anemia in myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82 (1993) 737-743
13. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92 (1998) 68-75
14. Terpos E., Mougiou A., Kouraklis A., Chatzivassili A., Michalis E., Giannakoulas N., et al., For The Greek MDS Study Group. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 118 (2002) 174-180
15. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
16. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 (2001) 958-965
17. Strupp C., Hildebrandt B., Germing U., Haas R., and Gattermann N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 17 (2003) 1200-1202
18. Moreno-Aspitia A., Colon-Otero G., Hoering A., Tefferi A., Niedringhaus R.D., Vukov A., et al., North Central Cancer Treatment Group. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 107 (2006) 767-772
19. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 February (6) (2005) 549-557
20. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Myelodysplastic syndrome-003 study investigators. Lenalidomide in the myelodysplastic syndrome with chromosome del 5q. N Engl J Med 355 October (14) (2006) 1456-1465
21. Aul C., Runde V., and Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82 (1993) 2967-2974
22. Giagounidis A.A., Haase S., Germing U., Schlegelberger B., Wilkens L., Busche G., et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 84 (2005) 389-394
23. Lubbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114 (2001) 349-357
24. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
25. Juneja H.S., Jodhani M., Gardner F.H., Trevarthen D., and Schottstedt M. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Hematol 46 (1994) 338-342
26. Stewart B., Verdugo M., Guthrie K.A., Appelbaum F., and Deeg H.J. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 123 (2003) 879-885